BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $40 price target The firm sees the company’s AVTX-009 as having best-in-class features that could support preferred positioning in several large indications. Avalo’s lead efforts are in hidradenitis suppurativa, where BTIG continues to expect significant reward for more active treatment options, even after key IL-17A/F inhibitors are expected to be well-established, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics initiated with a Buy at Lucid Capital
- Avalo Therapeutics (AVTX) Is a Potential Hidden Gem with Significant Risk
- Avalo Therapeutics receives $69.4M in proceeds from exercise of warrants
- Avalo Therapeutics reports Q3 EPS ($2.83) vs ($22.83) last year
- Avalo Therapeutics, Inc. (AVTX) Q3 Earnings Cheat Sheet